MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia (NCT07492771) | Clinical Trial Compass
Not Yet RecruitingPhase 1
MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia
South Korea18 participantsStarted 2026-06-15
Plain-language summary
The purpose of this study is to evaluate the safety and tolerability of a single intravenous dose of MP101 administered in addition to standard antibiotic therapy in adult patients with acute Pseudomonas aeruginosa pneumonia. The study will also assess the pharmacokinetic and pharmacodynamic characteristics of MP101 and its antibacterial activity, including changes in P. aeruginosa burden in sputum and changes in susceptibility to MP101 and concomitant antibiotics.
Who can participate
Age range
19 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Subjects aged 19 years or older.
* Clinical diagnosis of acute pneumonia with radiologic evidence of pulmonary infiltrates.
* Confirmed Pseudomonas aeruginosa (PA) infection via valid respiratory specimens.
* PA isolate demonstrates susceptibility to MP101 and non-susceptibility to current antibiotic therapy.
* Adequate organ function as defined by hematological, hepatic, and renal laboratory parameters .
Exclusion Criteria:
* Persistent septic shock or hemodynamically unstable condition.
* Active pulmonary tuberculosis or suspected non-bacterial pneumonia.
* Significant pleural effusion or lung abscess requiring therapeutic drainage.
* Clinically significant cardiovascular, hepatic, or renal impairment .
* Immunocompromised status or history of hematological malignancies.
* Known hypersensitivity to bacteriophages, study components, or concomitant antibiotics.
* Participation in another clinical trial within 30 days prior to screening.
* Any medical condition that, in the opinion of the investigator, would make the subject unsuitable for the study.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Incidence and frequency of adverse events (AEs), adverse drug reactions (ADRs), serious adverse events (SAEs), and serious adverse drug reactions (SADRs) occurring after administration of MP101.
Timeframe: Throughout the clinical trial period from screening through Day 29 (D29)